EVENTS | VIEW CALENDAR
Galapagos, Janssen to collaborate
MECHELEN, Belgium—In an effort to discover and validate novel targets in the field of oncology, Galapagos NV recently announced a new two-year target discovery collaboration between Janssen Pharmaceutica and BioFocus DPI, Galapagos' service division.
BioFocus DPI will apply Galapagos' proprietary adenoviral platform to identify novel drug targets for the development of cancer therapies.BioFocus DPI will perform assay development, screening of the SilenceSelect and FLeXSelect adenoviral libraries, and target validation.
Target discovery in in vitro assays may provide novel drug targets for cancer areas with an unmet medical need. BioFocus DPI receives an upfront payment of EUR 2.9 million. In total, BioFocus DPI may receive additional research, acceptance, license and development fees of up to EUR 7.6 million should certain predetermined criteria be achieved.
"This marks BioFocus DPI's first target discovery agreement in oncology, as well as the largest target discovery agreement to date for the service division," says Onno van de Stolpe, chief executive officer of Galapagos.BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of preclinical candidates.
BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets and compound libraries.